Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
Open accessThe DOI matches its Crossref record; 165 of the 166 references it cites were found in a registry or an index.
Abstract
Cetuximab and panitumumab, as the highly effective antibodies targeting epidermal growth factor receptor (EGFR), have clinical activity in the patients with metastatic colorectal cancer (mCRC). These agents have good curative efficacy, but drug resistance also exists at the same time. The effects of KRAS, NRAS, and BRAF mutations and HER2 amplification on the treatment of refractory mCRC have been elucidated and the corresponding countermeasures have been put forward. However, the changes in EGFR and its ligands, the mutations or amplifications of PIK3CA, PTEN, TP53, MET, HER3, IRS2, FGFR1, and MAP2K1, the overexpression of insulin growth factor-1, the low expression of Bcl-2-interacting mediator of cell death, mismatch repair-deficient, and epigenetic instability may also lead to drug resistance in mCRC. Although the emergence of drug resistance has genetic or epigenetic heterogeneity, most of these molecular changes relating to it are focused on the key signaling pathways, such as the RAS/RAF/mitogen-activated protein kinase or phosphatidylinositol 3-kinase/Akt/mammalian target of the rapamycin pathway. Accordingly, numerous efforts to target these signaling pathways and develop the novel therapeutic regimens have been carried out. Herein, we have reviewed the underlying mechanisms of the resistance to anti-EGFR therapy and the possible implications in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Elevated plasma levels of EGFR ligands such as epiregulin (EREG) and amphiregulin (AREG) may be indicative of resistance to anti-EGFR therapy [29].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [29]
In the citing paper
“Whereas PI3K inhibitors and mTOR inhibitors have been developed and approved for clinical trials in PIK3CA-mutated solid tumors [164].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [164]
In the citing paper
“There is increasing evidence that aberrant activation of this pathway is associated with anti-EGFR treatment resistance [164].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [164]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“8 million new CRC cases and 881,000 deaths were estimated to have occurred in 2018 and the incidence and mortality rank third and second, respectively [1].”
BackgroundBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“Among them, BRAF accounts for >90% of BRAF mutations, which refers to the T-to-A changing at nucleotide 1799 and a substitution of valine to glutamic acid [64].”
BackgroundComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Global patterns and trends in colorectal cancer incidence and mortality
Arnold, M., Sierra, M. S., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2017) · Gut · doi:10.1136/gutjnl-2015-310912 · Cited by 5,228 · cited 1×
“Fortunately, although the incidence and mortality of CRC in some underdeveloped areas are still increasing, they are declining in the whole world, especially in the developed countries [3].”
Backgroundras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions*
JONES, J. I., & CLEMMONS, D. R. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-3 · Cited by 4,710
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · cited 1×
“transcription 3 (STAT3) [124]; besides, HGFR can also be coupled with HER3 to form a heterodimer under certain conditions [125].”
Background
Cited by
Items 101–125 of 125
Sánchez-Muñoz, K., & Pinto-Llerena, J. (2022) · International Journal of Clinical Oncology and Cancer Research · doi:10.11648/j.ijcocr.20220702.14
Shponka, I. S., Kharkhalis, I. K., & Poslavska, О. V. (2023) · Medicni perspektivi · doi:10.26641/2307-0404.2023.1.275703
Archana, & Deshmukh, R. (2024) · Current Cancer Therapy Reviews · doi:10.2174/0115733947279599231208095726
Conclusions: the future of RAS drug discovery
Gill, A. L., & Shokat, K. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00009-7
Kumaravel, V., Pal, P., Pal, S., Chourasia, P., Tamkeen, R., Naigotriya, S., & Das, K. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4996094
Zhu, Y., Fu, X., & Dai, Y. (2025) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/194037 · Cited by 2
“11 The longevity of patients with mCRC has recently increased as a result of breakthroughs in targeted therapy.”
Molecularly Targeted Therapy for Gallbladder Cancer
Pierce, K., & Gomez, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-76746-3_16
Salavatipour, M. S., Tavakoli, S., Barkhordar, M., Seyhoun, I., Vousooghi, N., Vaezi, M., Ghaderi, A., Bakhtiari, T., Ghavamzadeh, A., Verdi, J., et al. (2025) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.43859
“26,27 The combination of cetuximab antibody with chemotherapy, including irinotecan/5-FU/leucovorin (FOLFIRI) and weekly oxaliplatin/5-FU/leucovorin (FUFOX), showed positive outcomes as a primary treatment option for advanced gastric or gastroesophageal junction adenocarcinoma in phase II trials.”
Detection of postoperative recurrence in colorectal cancer: Exploring the value of liquid biopsy
Костюченко, В. В., Vynnychenko, I. O., Moskalenko, Y., & Pohorila, V. (2025) · Regulatory Mechanisms in Biosystems · doi:10.15421/0225020 · Cited by 1
Chauhan, B., & Paul, T. J. (2025) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-96-4959-4_6
Huang, J., Li, Z., He, D., Li, X., Wang, Y., Li, Q., Wang, D., & Xiaoyan, F. (2025) · Oncology Letters · doi:10.3892/ol.2025.15154
“EGFR inhibitor therapy was not considered due to the NGS result and the evidence suggesting that patients with HER2‑positive CRC are highly resistant to EGFR inhibi‑ tors (11,12).”
Self-citationEpigenetic Regulation and Targeted Therapy in Gall Bladder Cancer
Singh, D., & Mukherjee, S. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70403
“Gene amplification and gall bladder cancer prognosis have both been associated with EGFR overexpression; however, only just 4% of patients with gall bladder cancer have EGFR mutations, making them extremely uncommon [40].”
Loganathan, S., Hashim, N. M., Wan‐Ibrahim, W. I., & Rashid, N. N. (2025) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2025.100414
The direct and indirect effects of attenuated salmonella typhimurium on intestinal tumour epithelium
Mackie, G. M. (2024) · University of Birmingham Institutional Research Archive (University of Birmingham)
Research Progress in the Treatment of Colon Cancer
侯, 文. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15102776
Akbarzadeh-Khiavi, M., & Safary, A. (2025) · Medical Journal of Tabriz University of Medical Sciences and Health Services · doi:10.34172/mj.025.33809
David, A. P. L., Galvez, M. I. P., Chua, S. A. A., Leaño, D. M. G., Sacdalan, D. L., & Garcia, R. L. (2026) · Cells · doi:10.3390/cells15040349
“Activating mutations in KRAS and NRAS correlate with non-responsiveness to EGFR-targeted therapy against CRC [65].”
Marei, H. E. S., Pozzoli, G., Caratelli, S., & Cenciarelli, C. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04258-7
“Especially in KRAS-mutated cancers, using the improved affinity interactions of some FcγR variants, such as CD16 158V , with therapeutic antibodies can increase ADCC and overcome resistance mechanisms [126].”
Qasim, R., & Bouchnita, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.05.730529
“These pathways drive cancer cell proliferation by promoting chronic activation of transcription factors through the cell cycle, as shown in Figure 1 [5].”
Liu, C., & Wang, Y. (2026) · International Journal of Surgical Pathology · doi:10.1177/10668969261457880
Self-citationSitholumusa, M. U. I., Deng, S., Li, Z., Zhang, Y. F., Li, M., Chen, B., Zhao, J., Sun, C., & Kai, G. (2026) · Clinical Traditional Medicine and Pharmacology · doi:10.1016/j.ctmp.2026.200295 · Cited by 2
Pharmacogenomic biomarkers in oncology: evidence, clinical utility, and barriers to implementation
Vishwash, S. K., Soni, R. B., Kosey, S., & Sood, R. (2026) · Journal of Chemotherapy · doi:10.1080/1120009x.2026.2709952
Raza, A., Raza, M. A., Khan, J., & Ajazuddin (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156645
Osumi, H., Shinozaki, E., Nakamura, Y., Esaki, T., Yasui, H., Taniguchi, H., Satake, H., Sunakawa, Y., Komatsu, Y., Kagawa, Y., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117112
IPO5 contributes to cetuximab resistance in colorectal cancer by modulating Ras signaling
Yuan, Q., Lu, S., He, X., Zheng, L., Liu, L., Chen, Y., Zhang, W., Li, X., Li, X., & 李学农 (2026) · iScience · doi:10.1016/j.isci.2026.117714
“The half-maximal inhibitory concentration (IC 50 ) was determined via a nonlinear regression analysis (four-parameter logistic [4 PL] model) using GraphPad Prism 9.0 (GraphPad Software, San Diego, USA).”
Influential
Metadata
- Authors
- Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N.
- Affiliations
- Department of Gastrointestinal Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, P. R. China
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Venue
- Gastroenterology Report
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-06-01
- Volume
- 8
- Issue
- 3
- Pages
- 179-191
- ISSN
- 2052-0034 (ISSN-L)
- PMC
- PMC7333932
- OpenAlex
- W3037750477
- Cited by
- 119
- References
- 166
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 23 · 2023: 17 · 2022: 23 · 2021: 17 · 2020: 1
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Gastroenterology report (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81871994, 81701834)
- Guangdong Natural Science Foundation (2019B151502063)
- Guangdong Science and Technology Planning Program (20190202018)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- anti-EGFR therapy, metastatic colorectal cancer, drug resistance, cetuximab, panitumumab, EGFR mutation, KRAS, NRAS, BRAF, HER2 amplification, PIK3CA, PTEN, TP53, MET, HER3, insulin receptor substrate 2, FGFR1, MEK1, insulin-like growth factor I, mismatch repair deficiency, epigenetic instability, Ras/Raf/MEK signaling, PI3K/AKT/mTOR pathway, combination therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.